Skip to content

Study · In vitro (cells) · 2008

3 results

Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist.

Seitz S, Hohla F, Schally AV, Moder A, Engel JB, Horn F, Varga J, Zarandi M, Ortmann O, Köster F, Buchholz S

Oncology reports1 Nov 2008Cited by 9 (Europe PMC)

PMID18949435 (opens in a new tab)DOI10.3892/or_00000143 (opens in a new tab)PepBankPUB-18949435
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In ZR 75 and SKBR 3 human breast cancer cell lines, direct stimulation with GHRH(1-29)NH2 increased proliferation in vitro.

    In plain wordsIn lab-grown human breast cancer cells, GHRH(1-29)NH2 made the cells multiply more.

    Peptide
    Sermorelin
    Outcome
    IncreaseBreast cancer cell proliferation
    Study

    humann: not reported in source

    ZR 75 and SKBR 3 human breast cancer cell lines
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The proliferation in vitro of ZR 75 and SKBR 3 was increased after direct stimulation with GHRH(1-29)NH2.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 02LabEndogenous levelIn vitro (cells)Mechanism

    SKBR 3 and ZR 75 human breast cancer cells expressed the cells' own GHRH ligand and the pituitary type of GHRH receptor.

    In plain wordsIn lab-grown human breast cancer cells, the cells made their own GHRH and its pituitary-type receptor.

    Peptide
    Sermorelin
    Outcome
    Not applicableGHRH ligand and receptor expression
    Study

    humann: not reported in source

    ZR 75 and SKBR 3 human breast cancer cell lines
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    SKBR 3 and ZR 75 expressed the GHRH ligand as well as the pituitary type of GHRH-receptor, which likely appears to mediate the antiproliferative mechanisms in these cell lines.

    This result measures the body's own Sermorelin. Nobody was given the peptide. It is not evidence about taking it.

Studies that did not test the peptide alone1

In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Sermorelin.

  1. 03LabNot a test of Sermorelin aloneIn vitro (cells)Activity measurement

    In ZR 75 and SKBR 3 human breast cancer cells, the GHRH antagonist JMR-132 nullified the proliferative effect of GHRH.

    In plain wordsIn lab-grown human breast cancer cells, the drug JMR-132 blocked the growth-promoting effect of GHRH.

    Peptide
    Sermorelin
    Outcome
    DecreaseEffect of GHRH antagonist JMR-132 on GHRH-induced proliferation
    Study

    humann: not reported in source

    ZR 75 and SKBR 3 human breast cancer cell lines
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    The GHRH antagonist JMR-132 had a significant antiproliferative activity in the absence of GHRH and nullified the proliferative effect of GHRH in these cell lines.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.